Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions
Severe Preeclampsia
Interventions
DRUG

Labetalol

it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent

DRUG

Nitroglycerine

a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses

DRUG

Nifedipine

dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive

All Listed Sponsors
lead

Sohag University

OTHER

NCT06265415 - Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine | Biotech Hunter | Biotech Hunter